Literature DB >> 11818328

ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells.

Neil Davie1, Stephen J Haleen, Paul D Upton, Julia M Polak, Magdi H Yacoub, Nicholas W Morrell, John Wharton.   

Abstract

We determined the distribution of ET(A) and ET(B) receptors in pulmonary arteries from pulmonary hypertensive patients and control subjects, using in vitro autoradiography, and investigated their role in mediating the proliferative effects of endothelin-1 (ET-1) on distal human pulmonary artery smooth muscle cells (PASMCs). Distal arteries possessed more medial [(125)I]-ET-1 binding sites (105 +/- 10 versus 45 +/- 6 amol/mm(2); p < 0.001) and a greater proportion of ET(B) receptors than proximal arteries (36 +/- 3% versus 3 +/- 1%; p < 0.001). Receptor density in distal arteries and lung parenchyma was twofold greater (p < 0.05) in pulmonary hypertensive patients than in control subjects. ET-1 (10(-9)-10(-7) mol/L) stimulated DNA synthesis (147 +/- 10% of control subjects; p < 0.05) and attenuated the antiproliferative action of cicaprost and forskolin on PASMCs, these effects being mediated via ET(A) and ET(B) receptors. Serum-stimulated proliferation was attenuated by inhibiting either endogenous ET-1 release with phosphoramidon (10(-5) mol/L) or its action with PD145065 (10(-5) mol/L). Cicaprost (10(-10)-10(-7) mol/L) inhibited ET-1 release from PASMCs (49 +/- 16% of control after 24 h; p < 0.001) and increased intracellular cAMP levels, whereas ET(B) receptor stimulation selectively reduced cAMP levels. In conclusion, ET(A) and ET(B) receptors are differentially distributed in human pulmonary arteries. Both receptors promote the proliferation of PASMCs in vitro and may contribute to vascular remodeling in pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11818328     DOI: 10.1164/ajrccm.165.3.2104059

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  69 in total

1.  The role of endothelin in the pathogenesis of heart failure.

Authors:  John R Teerlink
Journal:  Curr Cardiol Rep       Date:  2002-05       Impact factor: 2.931

2.  Clinical trials of endothelin antagonists in heart failure: publication is good for the public health.

Authors:  N F Kelland; D J Webb
Journal:  Heart       Date:  2007-01       Impact factor: 5.994

3.  Biomechanical Forces and Oxidative Stress: Implications for Pulmonary Vascular Disease.

Authors:  Evgeny A Zemskov; Qing Lu; Wojciech Ornatowski; Christina N Klinger; Ankit A Desai; Emin Maltepe; Jason X-J Yuan; Ting Wang; Jeffrey R Fineman; Stephen M Black
Journal:  Antioxid Redox Signal       Date:  2019-03-19       Impact factor: 8.401

4.  Regulation of Bcl-xL expression in lung vascular smooth muscle.

Authors:  Yuichiro J Suzuki; Hiroko Nagase; Chi Ming Wong; Shilpashree Vinod Kumar; Vivek Jain; Ah-Mee Park; Regina M Day
Journal:  Am J Respir Cell Mol Biol       Date:  2007-02-01       Impact factor: 6.914

5.  Approach to patients with heart failure and pulmonary hypertension.

Authors:  Paul R Forfia
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-08

6.  Modafinil improves monocrotaline-induced pulmonary hypertension rat model.

Authors:  Hyeryon Lee; Kwan Chang Kim; Min-Sun Cho; Suk-Hyo Suh; Young Mi Hong
Journal:  Pediatr Res       Date:  2016-03-09       Impact factor: 3.756

7.  Trypanosoma cruzi infection activates extracellular signal-regulated kinase in cultured endothelial and smooth muscle cells.

Authors:  Shankar Mukherjee; Huan Huang; Stefka B Petkova; Chris Albanese; Richard G Pestell; Vicki L Braunstein; George J Christ; Murray Wittner; Michael P Lisanti; Joan W Berman; Louis M Weiss; Herbert B Tanowitz
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

8.  Safety and tolerability of bosentan in the management of pulmonary arterial hypertension.

Authors:  Kari E Roberts; Ioana R Preston
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

9.  Ambrisentan for the treatment of pulmonary arterial hypertension.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

10.  Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension.

Authors:  Annette S Droste; David Rohde; Mirko Voelkers; Arthur Filusch; Thomas Bruckner; Mathias M Borst; Hugo A Katus; F Joachim Meyer
Journal:  Respir Res       Date:  2009-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.